[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Affiliated People's Hospital of Ningbo University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":156},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,74,102,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100638742","phase-2-lisaftoclax-for-prevention-of-differentiation-syndrom-in-acute-promyelocytic-leukemia-patients-100638742",false,"NCT07597941","Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients","Lisaftoclax for Prevention of Differentiation Syndrom (DS) in Acute Promyelocytic Leukemia (APL) Patients : An Open-lable, Single-arm, Multicenter, Phase Ⅱ Clinical Trail","Inclusion Criteria:\n\n* 1\\. Patients aged ≥ 16 years old.\n* 2\\. Confirmed diagnosis of acute promyelocytic leukemia (APL) by morphology, flow cytometry, and cytogenetics\u002Fmolecular testing.\n* 3\\. ECOG performance status 0-2.\n* 4\\. Adequate organ function:\n* Serum creatinine ≤ 1.5 × ULN\n* Total bilirubin ≤ 2 × ULN\n* AST\u002FALT ≤ 3 × ULN\n* 5\\. Able to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Concurrent participation in another interventional clinical trial.\n* 2\\. History of other malignancies within the past 5 years (except cured basal cell carcinoma or in situ cervical cancer).\n* 3\\. Severe uncontrolled infection or other serious underlying diseases that may interfere with study treatment or follow-up.\n* 4\\. Known hypersensitivity to lisaftoclax, ATRA, ATO, or any components of the study regimen.\n* 5\\. Pregnant or breastfeeding women.","ALL","16 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","This study is to assess the efficacy and safety of Lisaftoclax for prevention of DS in APL patients undergoing ATRA\u002FATO induction regimen.",[27],"Acute Promyelocytic Leukemia (APL)",[29,30,31],"Acute Promyelocytic Leukemia","Lisaftoclax","Differentiation Syndrom","NOT_YET_RECRUITING","2026-06-26",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":20},"2026-07",{"date":40,"type":20},"2028-12",{"name":42,"class":43},"The Affiliated People's Hospital of Ningbo University","OTHER_GOV",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100624759","phase-3-prevention-of-delayed-cinv-after-autologous-transplant-olanzapine-containing-regimen-vs-dexamethasone-containing-regimen-100624759","NCT07413809","Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen","A Prospective, Multicenter, Randomized Controlled Trial of Fosaprepitant Combined With Tropisetron and Multi-Day Olanzapine Versus Fosaprepitant Combined With Tropisetron and Dexamethasone for the Prevention of Delayed Nausea and Vomiting Induced by High-Dose Chemotherapy in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Patients with multiple myeloma who are indicated for autologous hematopoietic stem cell transplantation;\n* Preconditioning regimen consists of melphalan at a dose of 200 mg\u002Fm²;\n* ECOG performance status score of 0 to 2;\n* Age \\>18 years and \\\u003C65 years;\n* Expected survival time \\>3 months;\n* Absence of intracranial hypertension, gastrointestinal obstruction, or other causes of refractory vomiting;\n* Ability to understand and provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of nausea or vomiting within 48 hours prior to enrollment, with prior use of antiemetic medications;\n* Current use or use within the past month of CYP3A4 inducers, inhibitors, or substrate drugs;\n* History of hypersensitivity to fosaprepitant or olanzapine;\n* Serum creatinine clearance \\\u003C60 mL\u002Fmin;\n* Inability to receive treatment and follow-up at the designated study site, or inability to comprehend, comply with the study protocol, or provide informed consent.","18 Years","65 Years",{"count":54,"type":20},92,[24],"This study employs a prospective, multicenter, randomized, two-arm design aimed at evaluating the efficacy and safety of the FTO regimen in preventing delayed chemotherapy-induced nausea and vomiting (CINV) following high-dose chemotherapy for hematopoietic stem cell transplantation (HSCT). A total of 92 patients with multiple myeloma who were indicated for autologous HSCT were enrolled. The primary endpoint was to compare the complete response (CR) rates of the FTO regimen versus the FTD regimen in the delayed phase (24-240 hours after chemotherapy) for preventing nausea and vomiting induced by high-dose chemotherapy during HSCT.",[58],"Multiple Myeloma",[60,58,61,62,63],"Delayed vomiting","Fosaprepitant","Olanzapine","Tropisetron","RECRUITING","2026-02-12",{"date":67,"type":36},"2026-02-17",{"date":69,"type":36},"2025-10-31",{"date":71,"type":20},"2027-09",{"name":42,"class":43},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100556059","phase-3-comparison-study-of-eap-and-disease-specific-chemotherapy-regimens-in-hematopoietic-stem-cell-mobilization-for-lymphoma-100556059","NCT06520163","Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","A Prospective, Multicenter, Randomized Controlled Trial Comparing the Efficacy and Safety of Etoposide, Cytarabine, and PEG-rhG-CSF Combination Therapy vs. Disease-Specific Chemotherapy for Hematopoietic Stem Cell Mobilization in Lymphoma","Inclusion Criteria:\n\n* Diagnosed with non-Hodgkin's lymphoma before enrollment.\n* Indication for autologous stem cell transplantation (ASCT).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0\\~1.\n* Achieved complete remission after multiple courses of chemotherapy.\n* Life expectancy ≥ 3 months.\n* Subjects must be able to understand the protocol and sign the informed consent.\n\nExclusion Criteria:\n\n* Cardiac function class II or higher or cardiac ejection fraction \\\u003C 40%.\n* Serum direct bilirubin (DBIL) more than twice of the upper limit of normal (ULN).\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) more than three times the upper limit of normal (ULN).\n* Serum creatinine clearance rate ≤ 50%.\n* Patients with active infection.\n* History of prior hematopoietic stem cell mobilization.","75 Years",{"count":83,"type":20},99,[24],"This study utilizes a prospective, multicenter, randomized two-arm design to evaluate the efficacy and safety of the etoposide, cytarabine, and pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) combination therapy (EAP regimen) in mobilizing hematopoietic stem cells in patients with non-Hodgkin's lymphoma (NHL). A total of 99 NHL patients will be enrolled as research subjects and will be randomly allocated in a 2:1 ratio to compare the EAP regimen versus disease-specific chemotherapy mobilization regimen. The primary endpoint is the proportion of patients achieving the ideal collection value after a single collection (CD34+ cells ≥5×10\\^6\u002Fkg).",[87,88],"Non-Hodgkin's Lymphoma","Hematopoietic Stem Cell Mobilization",[87,90,91,92],"Disease-Specific Chemotherapy","Hematopoietic stem cell mobilization","Etoposide, Cytarabine Combined with PEG-rhG-CSF","2025-11-27",{"date":95,"type":36},"2025-12-04",{"date":97,"type":36},"2024-08-01",{"date":99,"type":20},"2026-08",{"name":42,"class":43},17,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":81,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100556060","phase-3-comparison-study-of-eap-and-cg-regimens-for-mobilizing-hematopoietic-stem-cells-in-multiple-myeloma-patients-100556060","NCT06520176","Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients","A Prospective, Multicenter, Randomized Controlled Study of Etoposide, Cytarabine Combined With Pegfilgrastim vs. Cyclophosphamide Combined With G-CSF for Hematopoietic Stem Cell Mobilization in Newly Diagnosed Multiple Myeloma Patients","Inclusion Criteria:\n\n* 1\\. Patients newly diagnosed as multiple myeloma.\n* 2\\. Indication for ASCT.\n* 3\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0\\~1.\n* 4\\. Life expectancy ≥ 3 months.\n* 5\\. Subjects must be able to understand the protocol and sign the informed consent.\n\nExclusion Criteria:\n\n* 1\\. Cardiac function class II or higher or cardiac ejection fraction \\\u003C40%.\n* 2\\. Serum direct bilirubin (DBIL)\\>2× upper limit of normal (ULN).\n* 3\\. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>3× ULN.\n* 4\\. Serum creatinine clearance rate≤30%.\n* 5\\. Patients with active infection.\n* 6\\. Previously received hematopoietic stem cell mobilization.",{"count":83,"type":20},[24],"This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and Pegfilgrastim (EAP regimen) for mobilizing hematopoietic stem cells in patients with newly diagnosed multiple myeloma (NDMM). A total of 99 NDMM patients will be enrolled and randomly assigned to receive either the EAP regimen or the GC regimen (cyclophosphamide+ G-CSF) to mobilize hematopoietic stem cells. Subsequently, the mobilization effects and adverse reactions of all patients will be observed and compared.",[58,88],[58,114,115,116,88],"Etoposide","Cytarabine","PEG-rhG-CSF","2024-07-20",{"date":119,"type":36},"2024-07-25",{"date":121,"type":20},"2024-08",{"date":123,"type":20},"2026-12",{"name":42,"class":43},16,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":81,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":137,"conditions":138,"keywords":143,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":73},"100479892","phase-1-study-of-car-t-cell-therapy-in-the-treatment-of-relapsedrefractory-hematological-malignancies-100479892","NCT05528887","Study of CAR-T Cell Therapy in the Treatment of Relapsed\u002FRefractory Hematological Malignancies","Safety and Efficacy Study of Chimeric Antigen Receptor T (CAR-T) Cells in the Treatment of Relapsed\u002FRefractory Hematological Malignancies","Inclusion Criteria:\n\n1. Histological diagnosis of hematological malignancies (such as lymphoma, myeloma, leukemia) refractory to, or relapsing after standard therapy.\n2. Positive expression of specific antigens.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0\\~2.\n4. Adequate organ functions:\n\n   * Serum bilirubin ≤ 35 μmol\u002FL;\n   * Serum aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) \\\u003C 2;\n   * Serum creatinine (Cr) ≤ 2 × upper limit of normal (ULN);\n   * Brain natriuretic peptide (BNP)\\\u003C80 pg\u002FmL.\n5. Subjects must be able to understand the protocol and be willing to enroll the study, sign the informed consent, and be able to comply with the study and follow-up procedures.\n\nExclusion Criteria:\n\n1. History of allergy to any of the drugs involved in the protocol.\n2. History of cardiac diseases:\n\n   * Left ventricular ejection fraction (LVEF) \\\u003C 50%;\n   * Class III or IV heart failure as defined by the New York Heart Association (NYHA).\n3. History of another malignancy tumor.\n4. Active hepatitis C (HCV), hepatitis B (HBV), human immunodeficiency virus (HIV), or syphilis infection.\n5. Patients with any contraindications to allogeneic hematopoietic stem cell transplantation.\n6. Uncontrolled fungal, bacterial, viral, or other infection.\n7. Female subjects who are pregnant or lactating.",{"count":134,"type":20},10,[136],"PHASE1","The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with relapsed\u002Frefractory hematological malignancies.",[139,140,141,142],"Relapsed\u002FRefractory Hematological Malignancies","Lymphoma","Myeloma","Leukemia",[144,145,146,147],"CD19 CAR-T","BCMA CAR-T","CD7 CAR-T","CD123 CAR-T","2022-09-01",{"date":150,"type":36},"2022-09-06",{"date":152,"type":36},"2021-09-16",{"date":154,"type":20},"2026-06",{"name":42,"class":43},""]